New late-breaking data presented on Day 3 of EuroPCR 2026 highlighted evolving approaches to antiplatelet therapy, transcatheter treatment of pure aortic regurgitation and procedural optimization in bicuspid TAVR

Day 2 hotline data at EuroPCR 2026 highlighted improved outcomes with FFR-guided PCI in TAVI, comparable 10-year survival with PCI and CABG in left main disease and consistent LAAC benefits across age groups.

At EHRA 2026, new research from Dr Kerollos Abdelsayed highlighted perioperative inflammation as a modifiable driver of conduction disturbances after TAVI, opening the door to novel pharmacologic and device-based solutions.

Balloon aortic valvuloplasty (BAV) has experienced a complex evolution in clinical practice, transitioning from an early therapeutic innovation to limited use, and more recently to a redefined role in the era of transcatheter aortic valve implantation (TAVI). In the first of our new practice pearls series, In Rhythm, Dr Gustavo Samaja (Sanatorio Colegiales, Buenos Aires, Argentina) shares practical insights into the contemporary role of BAV, including patient selection, procedural strategies, and its use as both a bridge and a decision-making tool. He also discusses how evolving healthcare systems and resource considerations continue to shape the balance between BAV and TAVI in everyday clinical practice.

The Evolut Low Risk trial (Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement; ClinicalTrials.gov identifier: NCT02701283) provides reassuring evidence that transcatheter aortic valve replacement (TAVR) ...

The EuroPCR 2024 meeting, the leading global conference in interventional cardiovascular medicine, was a hub of innovation and cutting-edge research. This year’s event in Paris brought together the world's foremost experts, researchers and clinicians to share the latest advancements and breakthroughs in the field. From novel therapeutic approaches to landmark clinical trials, EuroPCR 2024 provided a comprehensive overview of the current and future landscape of cardiovascular care. We selected our top three trials from this year’s late-breaking sessions:

Over the past two decades, the field of transcatheter aortic valve replacement (TAVR) has experienced remarkable advancement. Initially approved for patients with high and prohibitive surgical risk, TAVR has progressively extended its indications to all patients, regardless of surgical risk. ...

The prevalence of aortic stenosis (AS) has grown over the last few decades, as life expectancy has increased. AS is the most common valvular disease in the developed world and is found in up to 9.8% of individuals aged ≥75.1–3 The wide ...

Transcatheter aortic valve replacement (TAVR) has seen worldwide explosive growth. The current USA guidelines no longer use risk in choosing between TAVR and surgical aortic valve replacement, and the European guidelines have extended the recommendation for TAVR to lower risk ...